High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis
AIM:To study the cost-effectiveness of high-resolution microendoscopy(HRME)in an esophageal squamous cell carcinoma(ESCC)screening program in China.METHODS:A decision analytic Markov model of ESCC was developed.Separate model analyses were conducted for cohorts consisting of an averagerisk populatio...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 21; no. 18; pp. 5513 - 5523 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Baishideng Publishing Group Inc
14.05.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | AIM:To study the cost-effectiveness of high-resolution microendoscopy(HRME)in an esophageal squamous cell carcinoma(ESCC)screening program in China.METHODS:A decision analytic Markov model of ESCC was developed.Separate model analyses were conducted for cohorts consisting of an averagerisk population or a high-risk population in China.Hypothetical 50-year-old individuals were followed until age 80 or death.We compared three different strategies for both cohorts:(1)no screening;(2)standard endoscopic screening with Lugol’s iodine staining;and(3)endoscopic screening with Lugol’s iodine staining and an HRME.Model parameters were estimated from the literature as well as from GLOBOCAN,the Cancer Incidence and Mortality Worldwide cancer database.Health states in the model included non-neoplasia,mild dysplasia,moderate dysplasia,high-grade dysplasia,intramucosal carcinoma,operable cancer,inoperable cancer,and death.Separate ESCC incidence transition rates were generated for the average-risk and high-risk populations.Costs in Chinese currency were converted to international dollars(I$)and were adjusted to 2012dollars using the Consumer Price Index.RESULTS:The main outcome measurements for this study were quality-adjusted life years(QALYs)and incremental cost-effectiveness ratio(ICER).For the average-risk population,the HRME screening strategy produced 0.043 more QALYs than the no screening strategy at an additional cost of I$646,resulting in an ICER of I$11808 per QALY gained.Standard endoscopic screening was weakly dominated.Among the high-risk population,when the HRME screening strategy was compared with the standard screening strategy,the ICER was I$8173 per QALY.For both the high-risk and average-risk screening populations,the HRME screening strategy appeared to be the most cost-effective strategy,producing ICERs below the willingness-topay threshold,I$23500 per QALY.One-way sensitivity analysis showed that,for the average-risk population,higher specificity of Lugol’s iodine(>40%)and lower specificity of HRME(<70%)could make Lugol’s iodine screening cost-effective.For the high-risk population,the results of the model were not substantially affected by varying the follow-up rate after Lugol’s iodine screening,Lugol’s iodine test characteristics(sensitivity and specificity),or HRME specificity.CONCLUSION:The incorporation of HRME into an ESCC screening program could be cost-effective in China.Larger studies of HRME performance are needed to confirm these findings. |
---|---|
Bibliography: | Chin Hur;Sung Eun Choi;Chung Yin Kong;Gui-Qi Wang;Hong Xu;Alexandros D Polydorides;Li-Yan Xue;Katherine E Perzan;Angela C Tramontano;Rebecca R Richards-Kortum;Sharmila Anandasabapathy;Institute for Technology Assessment, Massachusetts General Hospital;Harvard Medical School, Boston, MA 02114, United States;Gastrointestinal Unit, Massa- chusetts General Hospital;Department of Endoscopy, Cancer Institute and Hospital, Chinese Academy of Medical Sciences;Department of Endoscopy, The First Hospital of Jilin University;Department of Pathology, The Mount Sinai Medical Center, Icahn School of Medicine;Department of Pathology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences;Department of Bioengineering, Rice University;Baylor Global Initiatives and the Baylor Global Innovation Center, Baylor College of Medicine Correspondence to: Chin Hur, MD, MPH, GI Health Outcomes Research, Massachusetts General Hospital, 101 Merrimac Street, 10th Floor, Boston, MA 02114, United States. chur@mgh.harvard.edu Telephone: +1-617-7244445 Fax: +1-617-7269414 Author contributions: Hur C, Choi SE, Richards-Kortum RR, Anandasabapathy S, Wang GQ and Xu H designed the study; Xue LY, Xu H, Wang GQ, Polydorides AD, Anandasabapathy S and Richards-Kortum RR acquired the data; Hur C, Choi SE, Kong CY, Anandasabapathy S, Richards-Kortum RR, Perzan KE and Tramontano AC wrote the manuscript. |
ISSN: | 1007-9327 2219-2840 |
DOI: | 10.3748/wjg.v21.i18.5513 |